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Figure 11.1 Data types commonly available for the analysis of chronic diseases
significant growth in the EHR uptake, and as a result, much of patient information collected in hospitals is now accessible in electronic formats. Simultaneously, the declining cost of genome sequencing has allowed for the possibility of creating large biobanks of linked clinical and genomic data sources. These databases are built upon the hypothesis that human genetic information (i.e., genotype) can help us to predict or augment our understanding of a patient's phenotype. While genome-wide association studies have illustrated that the links between genotype and phenotype are more complex than originally thought, there is still great potential for research to uncover how genomic factors are involved in different types of disease [4] . Exemplifying this purpose, a number of large EHR/biobank databases have been initiated, including the Electronic Medical Records and Genomics (eMERGE) network, the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH), the "i2b2" service created by the National Center for Biomedical Computing in the USA, the China Kadoorie Biobank, and the UK Biobank [5] [6] [7] .
We will now delve further into the types of information commonly encountered in EHR and genomic studies. Figure 11 .1 provides a summary of the different data types that may be available.
vital-sign summary values; and free text. While some information, such as laboratory data, is generally stored in a structured form, other information can be much more difficult to ascertain. Specific characteristics of the data are often unique to individual EHRs (and even between different specialties within the same hospital), making data extraction methods difficult to standardise across systems. For instance, drug prescription and dosage may be included in structured formats in some EHRs, while this information may only be included in free text in others.
Because EHR data are collected for clinical care, patient records are often partially missing, incorrect, systematically misleading, and contradictory. The process of extracting meaningful EHR data that reflects true patient physiology (this is often referred to in the literature as "phenotyping" the patient) is not a simple task. Hripcsak and Albers outline several of the associated challenges [8] . As various authors have identified, within the scope of machine-learning analysis, a pertinent drawback of EHR data is that the labels required for supervised learning may be confounded by the fact that care is being provided [9, 10] .
Particularly in chronic disease applications, measurements taken repeatedly over time are relevant for analysis. In terms of structured data, such measurements can include blood measures of various metabolites ("labs"), ICD10 codes, or specialised relevant clinical variables that are collected for particular diseases. Modelling these metrics directly can provide insight into a patient's physiological progression over time, as well as relevant comorbidities. For instance, there have been recent developments on using ICD10 codes and specialised clinical variables to model subtypes of disease progression [11] [12] [13] [14] . The type of data that is most relevant will depend, of course, upon the disease of interest and the availability within the record.
Free text in the medical notes also provides a potentially rich source of information regarding patient progression. However, the frequent misspellings, abundance of abbreviations, and multiple meanings of many medical terms means that advanced natural language processing (NLP) is often required to glean meaningful textual information beyond what is already present in the rest of the record.
Often particular diseases will involve specialised variables that may not be routinely collected in the EHR. For instance, in IBD, the specific locations of inflammation are particularly relevant to how physicians manage and treat the disease. Such information can be obtained through NLP of the free text, or, if such approaches have proved too difficult, manual extraction from the notes may be required. This is particularly the case for hospital systems where not all aspects of the patient record are available in electronic formats. Information contained in imaging studies such as MRIs or endoscopy images may also be relevant for analysis.
Genomic data
The declining cost of human genome sequencing means that genomic information has the potential to inform routine clinical practice. Human genetic variation is encoded in our DNA, which is composed of a long series of nucleotide base pairs (adenine, thymine, cytosine, and guanine). In the process of transcription, portions of DNA are converted into single-stranded RNA. Triplets of RNA bases (codons) are then translated into one of the 20 amino acids, which are the building blocks of proteins. The portions of the genome that encode proteins or other functional products are called genes. Only about 3% of the 3 billion nucleotide bases in the human genome constitute genes. Understanding the role of the rest of the genome is still a work in progress, but it is well-established that parts are involved in regulating gene expression (i.e., protein production). Heritable (and non-heritable) gene expression regulation can also be accomplished through changes to the macro-structure of the DNA through chemical alterations such as methylation. Such changes are termed "epigenetic" because they result in changes in gene expression without altering the underlying DNA sequence.
Human genomic variation can occur through many mechanisms. A single nucleotide polymorphism (SNP) is a single-base change in the DNA. SNPs can result in proteins with altered functionality, or, if within a regulatory region, changes in protein production. Across populations, there may be a few different common variants of a gene, termed alleles. Insertions and deletions of nucleotide bases (indels) and copy-number variants (CNVs) are also sources of inter-human variation. CNVs are large portions of the genome that have been deleted or duplicated; they constitute approximately 12% of human DNA [15] . Most multicellular organisms, including humans, have two copies of each chromosome. If the alleles on both chromosomes are the same, the allele is said to be homozygous; if the alleles differ, then it is said to be heterozygous.
Patient genetic information may be obtained in a variety of ways. Microarrays (also known as DNA chips) are perhaps the most common source of data in large databanks of phenotypic and genetic information. Microarrays are small chips that contain thousands of DNA probes attached to their surface. When a fluorescently labelled sample is introduced, any pieces of DNA that are complementary to the attached DNA probes will bind to the probe, indicating which sequences were present in the sample. Specialised microarrays can be created for specific purposes; for instance, the Immunochip is a microarray that has been designed to provide coverage of SNPs suspected to be involved in inflammatory diseases (e.g., IBD and rheumatoid arthritis).
Microarrays can be very cost-effective for wide coverage of common SNPs, but they do not provide information about every mutation in a patient's genome. Alternatively, whole-genome sequencing methods can be used to obtain the full genome sequence, which identifies SNPs and indels throughout the genome; CNVs are still sometimes difficult to identify. Illumina (USA), the current market leader in sequencing platforms, announced the sale of the first machines capable of the long-heralded "$1, 000" human genome in early 2014.
1 Some newer sequencing companies are offering longer read lengths, allowing for perhaps easier interpretation of CNVs. Full exome sequencing is another sequencing alternative, in which all protein-coding regions of a patient's genome are sequenced (as mentioned, the exome represents only about 1-3% of the human genome).
While sequencing data can provide information about a patient's genetic background, it does not answer which proteins are actually being produced in particular cells in the body at any given time (due to the advanced regulatory mechanisms involved). For this, mRNA levels or protein levels must be obtained. mRNA can be measured through microarrays (again, most useful for known and common gene transcripts), real-time quantitative polymerase chain reaction (allows for very specific exact measurements of the amount of mRNA in a sample), or RNAseq (which relies upon next-generation sequencing to assess RNA levels). Proteins levels can be assessed through antibody-based methods or mass spectrometry. mRNA and protein levels are less commonly available for large patient populations with EHR data, but they are increasingly being used (particularly in more targeted studies) to examine how gene expression levels influence disease phenotype.
There are a wide variety of additional data types that may also be relevant for a particular question. For instance, the microbiome, which consists of all microorganisms in the body, has been shown to be particularly relevant for IBD pathogenesis. The "exposome", the record of environmental exposures a given patient has been exposed to, is also important for unravelling the pathogenesis of many diseases [3] . Of course, a detailed record of such information is not available in nearly any setting, but thinking about how environmental exposures can influence disease progression can guide which information may be useful to collect.
A key aspect of any study of patient disease progression and modelling is a deep understanding of the data collected. It is important to ascertain, for instance, how a hospital's local practices may influence how one should interpret specific variables. The application of diagnosis codes is notoriously inconsistent, with coding practices varying by institution. Lab machinery may change over time, which means that reference ranges and the maximum/minimum possible values may shift. Interpreting such clinical data will likely require close consultation with physicians or nurses who are experienced with the hospital practices.
EVT applied to longitudinal data
Often when monitoring patients over long periods of time, as is the case for chronic disease, it is desirable to understand how recent trends in measured data points compare to a patient's previous levels and to those of the patient population. However, it is often only deviations beyond a certain range (i.e., "normal") that are of interest. For instance, for a patient with IBD, a physician may want to understand how concerning the results of a high C-reactive protein or lymphocyte level may be; the physician may be unconcerned if the value is within the normal patient range. For applications in which this is the case, it is desirable to focus specifically on modelling the extremes of the distribution of data points.
EVT is a branch of statistics that seeks to model the behaviour of the tails of distributions. Here, we will provide an introduction to the basic models and explain how they may be applied in healthcare settings. For more details, References 16 and 17 provide good introductions to EVT, each containing additional references for a more mathematical treatment of the models.
Classical EVT
There are two primary formulations for classical EVT models: a block maxima approach and a peaks-over-threshold approach. We start with a sequence of independently and identically distributed (IID) random variables, X 1 , . . . , X n ∼ F, collected at time points 1 . . . n. See Figure 11 .2 for a visual overview of these models. The block maxima approach attempts to model the maximum of these random variables obtained within a given time frame: M n = max(X 1 , . . . , X n ). The probability of M n being less than some value z m is therefore F(z m )
n . However, since we do not know F, and since estimates of F n will vary greatly depending upon the estimate of F, we instead focus on modelling the extremes themselves. In the limit of infinite data (n → ∞), M n will approach a dirac delta function on the maximum possible value of F. To avoid this, we re-normalise M n as M * n = Mn−μ σ for two constants, the scale: σ > 0 and the location: μ.
It can then be shown that, regardless of the distribution of F, in the limit as n → ∞, the distribution of M * n approaches the generalised extreme value (GEV) distribution [16] . The GEV cumulative distribution function (CDF) is as follows: where ξ is termed the shape parameter. G(x) is defined for 1 +
. The values of ξ correspond to three special cases of the GEV: when ξ > 0, the distribution is called the Frechet type; when ξ < 0, the distribution is called the Weibull; and when ξ = 0, the distribution is called the Gumbel. 2 In sum, this tells us that the maximum value of a set of IID variables collected over a period of time will follow a GEV distribution. We can fit the parameters for the GEV using training data from multiple periods of time with maximum likelihood or Bayesian methods, if desired.
As mentioned, an alternative perspective is to model points exceeding a set, high threshold. This allows us to use more of the data, rather than simply the maximum values within each time window. Here, we are interested in a slightly different question: the probability of seeing a point above the threshold, u. Formally, we are interested in
We can obtain this by building upon our findings for the GEV above. Because F(x) is a CDF, it tends towards one with large values of x. Therefore, the Taylor expansion of logF(x) ≈ F(x) − 1 with large x. Using this fact to rewrite our formulation of the GEV above, we can obtain [16] :
H (y) is the form of a family of distributions called the generalised Pareto distribution (GPD). As is evident, the GPD and GEV models are closely related; the parameter ξ is shared between the two models; and σ p is a function of σ and μ. It makes intuitive sense that the distribution governing the probability of high values above a set threshold will be related to the maximum value observed within a given time window. These two models form the cornerstone of classical EVT.As has been emphasised, these rely upon the assumption of IID data. In the case of a stationary time series, however, there are temporal dependencies in the data. Fortunately, it turns out that, given a time dependency that decreases with increasing time distance, the GEV model is still an appropriate model for block maxima. The parameters governing a series of IID datapoints versus those governing a stationary time series are different, but since the parameters are being fit anyway, this is not of practical importance. In the case of the exceedances-over-threshold model, the GPD model is no longer as appropriate because exceedances will tend to occur in clusters. For instance, a high value is more likely to be followed by a high value. Traditionally, the common way to manage this issue has been to "decluster" the data. This involves using a (typically rule-based) approach to identify clusters of exceedances, and to keep only the maximum value in the cluster. The resulting exceedances should still follow the GPD.
In the case of non-stationary data, it is also possible to model trends parametrically. For instance, if there is clear information that the values in a time series are increasing over time, the location parameter can be modelled as having a linear trend, for example in a simple case as μ(t) = a 0 + a 1 t. Or, if the occurence of extreme points is related to a covariate, this can also be directly modelled in the same way (time is really a special case of a covariate). Of course, more complex trends will require more sophisticated modelling techniques. We will come back to non-parametric methods for modelling non-stationary time series in Section 11.3.5.
EVT from a point process perspective
We will now take a slightly different approach, which is that of modelling a time series as a point process. We will define a set M (e.g., a defined period of time), upon which there is some stochastic process that generates events. The point process approach is also valid for higher dimensional space, though we will focus on the twodimensional case (value vs. time) here. The expected number of points in any subset of the time series is termed the intensity measure of the process: = E{N (M )}, for every M ⊂ M . The prototypical example of a point process is the Poisson process (PP), in which we model a homogeneous point process with the number of points according to the Poisson:
where λ is the Poisson parameter. We can also make λ a function of time to allow for a non-homogeneous PP. The general form for the likelihood of the PP is
We take this approach because it turns out that the block maxima and pointsover-threshold models (the GEV and GPD models just presented, respectively) are special cases of the point process approach. This makes the PP model often more useful when modelling in practice because all parameters of both models can be fit simultaneously. Given a sequence of IID random variables, the points that appear above a high threshold u converge to a non-homogeneous PP as the number of points, n → ∞ [16] . The intensity measure for a region [t 1 , t 2 ] can be derived to obtain
The PP likelihood with this intensity measure is then:
where n y is a scaling parameter (the number of years of data) and N (A) is the number of points exceeding the threshold. The parameters for the PP model for EVT can then be determined via maximum likelihood. Of course, Bayesian methods can also be used if a prior is specified over the model parameters, but we will not go into detail for those here. The PP approach is therefore very powerful because simply by fitting this single model, we obtain the parameters for the GEV, GPD, and Poisson: μ, σ, ξ, σ p , λ. We can then use the corresponding models to answer questions about the likelihood of observing a given value as the maximum in a time window, etc.
Practicalities
A few practical questions remain. For instance, how should the threshold be chosen? How should the model fit be evaluated?
In choosing a threshold, this is a trade-off between model bias and variance. A too-low threshold will lead to bias in the model because the assumption of a high threshold, which was needed to derive the limiting approximation, will be violated. A too-high threshold will mean that there is very little data with which to estimate the model, leading to large variance in parameter estimation. One approach is to use a mean residual life plot. In such a plot, the threshold u is varied and the GPD parameters are fit to the training data, D, for each u. A separate plot is then created for each u: m e , the mean of all excesses above a threshold w, where u < w < max(D), is plotted against w. While in practice this line will be rather jagged, it should roughly follow a linear trajectory with a slope equal to
. This comes from the fact that for a set of points
. Confidence bands can also be included using Monte Carlo sampling (see Reference 17 for more details).
Another approach for choosing the threshold is to again vary the threshold and assess how the parameters change. If the GPD is an appropriate model, the parameters chosen should be valid for any subset of the data above the high threshold. Therefore, the threshold can be chosen as the point at which the fitted model parameters begin to stabilise.
In some cases, a "high" threshold has already been established through clinical experience. Lab measurements, for instance, typically are accompanied by a reference range. Though this cutoff may need to be adjusted if a particular patient population has consistently elevated or low measurements, it can often serve as a first-estimate threshold. Alternatively, physiological factors may be informative for determining a threshold. For example, IBD patients often have persistently elevated CRP measurements above the "normal" reference maximum of 8 mg/L. However, clinical experience has shown that measurements of up to 40 mg/L are associated with viral infection, and measurements greater than this associated with either bacterial infection or systemic inflammation. Therefore, a cutoff of 40 may prove to be reasonable, depending upon the question at hand. In regards to model fit, of course standard approaches of using training and validation sets can be used to maximise the log-likelihood. It is also instructive to view the actual density in comparison to a histogram of the underlying data to qualitatively evaluate the model fit. In addition, the overall applicability of the model can be assessed via a quantile plot (Q-Q plot). In a Q-Q plot, the quantiles of the empirical distribution of the data are plotted versus the quantiles of the theoretical distribution (as obtained by the fitted model parameters). In a well-fitting model, the Q-Q plot should yield a line on the unit diagonal. As a note, if a covariate is built into the model (as was presented in the case of a non-stationary time series), the quantiles must be adjusted to take the changing distribution into account. Basically, the modelled variable must be standardised based upon the included covariates (see Reference 16, Chapter 6, for more details). A Q-Q plot can also be used to assess whether points are outliers. Points may appear to be outliers when plotted simply as a histogram, but a Q-Q plot can indicate whether the point is actually in-line with the fitted model.
Particularly in healthcare applications, it may be that all of the measurements are only positive-valued. In this case, it may be necessary to take the natural log transform of the data before fitting the model so as to ensure that the resulting probability distributions only have support over positive values.
In some cases, it is not actually the exceedances of a threshold that are of interest, but the shortfalls. In this case, the same machinery can be used, but the data can simply be transformed so as to make it mirror an extreme distribution. For instance, if examining a set of data D l where points below a low threshold u l are of interest, the data can be transformed as D T = −D l + c where c is a constant to ensure that all of the resulting data is again in the positive domain (if, for instance, the log transform is taken as described above).
Application of EVT models to healthcare
As presented, the EVT approach is well-suited for problems in which the points of interest are those that are positioned in the extremes. EVT has indeed been applied for many years to applications in environmental and financial applications. Recently, the theory has been extended to model extreme functions, with motivating applications from hospital monitoring of vital signs [18] . Within chronic disease, this theoretical approach has not been widely adopted. However, it is an appropriate model: particularly when examining measurements of blood metabolites for patients over long periods of time, it is often the deviations from normality that are of interest. To capture this information in a probabilistic sense, we can fit the EVT model to training data and use this model to describe and evaluate new patients.
We now present an example of simulated patient data to represent a lab series over time, to illustrate the points from this section of the chapter. For this illustration, we have simply taken a time series as samples from a constant-mean linear function over time, with Gaussian noise. While idealised, this patient time series is representative of the behaviour of many patient blood measurements over time. In Figure 11 .3, we show a sample time series, with a histogram of the entire set of simulated data to show the full distribution.
We then use maximum likelihood to fit the μ, σ, ξ , and λ parameters using (11.5). We then find σ p using (11.3). The effect of varying the threshold is shown in Figure 11 .4. As is evident, the μ, σ, and ξ parameters are quite constant as the threshold is varied, showing that any threshold greater than one results in a valid GPD model. As would be expected, as the threshold is increased, the λ parameter will decrease, because there will be fewer exceedances in a given time window.
In Figure 11 .5, we show the model fit with u = 1. We present superpositions of the empirical histograms with the model probability density functions or probability mass function (in the case of the Poisson), as well as Q-Q plots. As would be expected from such an idealised dataset, the model provides a very good fit to the data.
This model can then be used to ask various questions about a newly seen patient dataset. For example, one could calculate the probability of the number of exceedances 
Figure 11.4 Illustration of the effect of varying the cutoff threshold on the values of the fit parameters
seen within a given window of time, or the probability of seeing a given high value. Given enough data, this can be done in a patient-specific manner to make personalised estimates of severity at a given time point. Alternatively, to compare patients across time and cohorts, "severity" scores over time can be created that combine different aspects of these EVT models. For instance, a simple model that makes 
Figure 11.5 Model fit for simulated data extremes
an assumption of independence among the GPD, GEV, and Poisson can be used to combine information across these three characteristics [19] . Of course, in a healthcare application, it is important to validate that the extreme values actually correspond to periods of patient deterioration. This can be done by linking lab measurements with hospital admissions or other metrics of severity. For instance, in IBD, extremely high measurements of CRP are indicative of a relapse event. High CRP measurements in the record typically co-occur with multiple hospital admissions and/or surgery. Thus, probability densities over extreme CRP lab measurements are useful indicators of a patient's physiological state.
Of particular note, measurements are often repeated as a patient is monitored in-hospital, which will invalidate the assumption of the IID nature of the data for a PP. As was mentioned, one approach for dealing with this is to de-cluster the exceedances, so that only the highest value in a cluster of exceedances is retained. More advanced methods are described in the following section.
Advanced topics
As described above, it is possible to directly parameterise changing dynamics over time in an inhomogeneous PP. However, an alternative approach is to allow the complexity of the data itself to determine the model using non-parametric models. For instance, the intensity function can be modelled as a Gaussian process (GP) to provide a smooth function of events over time. Such a model is called a Gaussian Cox process (GCP) or a doubly stochastic PP. The initial presentation of full inference on this model with minimal approximations is from Reference 20. Their model, the sigmoidal GCP, models the intensity function as a GP squashed through a logistic function and scaled by a set maximum intensity. Their inference scheme was through MCMC. There have been further developments on this model recently, with a new variational Bayes scheme for inference [21] as well as an approach for modelling multiple-dependent GCPs [22] . In the latter approach, multiple latent underlying functions are modelled, as well as the parameters for the individual GCPs; the model was fit with multiple types of MCMC, in a similar fashion to the Adams model [20] .
Conclusions on EVT
EVT provides a useful way to assess and model "beyond-normal" patient measurements. This is particularly relevant for chronic disease applications, where there may not be readily available data-driven metrics through which to monitor patient severity over time. Such scoring metrics also can be used as input into clustering methods to better elucidate the underlying subtypes of a disease, which often points towards distinct biological mechanisms and involved genetic factors. We now shift towards this question.
Patient clustering
Many diseases have very heterogeneous trajectories. IBD is one such disease; patients vary greatly in their age of onset, the severity of their initial presentation, the frequency of relapse, the response to medication and surgery, etc. There are many other diseases (e.g., autism, asthma, heart disease) for which this heterogeneity is similar. Indeed, it is likely that within many broad disease categories, there are distinct subtypes [23] [24] [25] [26] [27] . Disease subtypes may be related to underlying genetics or to environmental factors that influence changes in gene expression patterns. Better understanding these subtypes will allow for both improved scientific understanding of disease physiology as well as progress towards "precision medicine" by enabling the delivery of personalised treatments.
Unsupervised machine-learning techniques provide a powerful way to probe the types of data now available to identify subgroups of patients. In this section, we will introduce various methodologies that can be used for patient clustering, using EHR and genetic data. Of course, this only represents a subset of possible clustering methods that may be used, and the most appropriate methods will depend on the specific question and the nature of the data. We will provide examples of how the overviewed methods have been extended for specific questions related to disease subtyping.
Clustering overview
There are a number of ways in which one can begin to assess groups of patients with similar characteristics. Of course, in this context any patient must first be represented by a set of features, which may include continuous, binary, categorical, or one of many other data types (as presented in Section 11.2). The input into a clustering model can either be the raw features (i.e., an N × D matrix, where N is the number of patients and D is the number of features) or a distance matrix specifying the distance between each patient in terms of some specified metric (i.e., a D × D matrix).
A very common first approach for clustering patient data is hierarchical clustering. Hierarchical clustering involves the iterative joining (or separating, if using divisive clustering) of the "most similar" groups of patients. Distance between data points of course must be defined; some example metrics are shown in Table 11 .1. There are additionally a number of ways in which the clusters can be co-joined. In many real-world applications, Ward's criterion, which minimises the covariance within clusters, often results in distinctive cluster identification when other methods (e.g. average linkage, maximum linkage) do not.
Clustering methods for time-series data, such as is available for many chronic disease and critical care medical applications, is often more challenging than clustering of static data because the distance metric between two time-series is less well-defined. Relevant distance metric options include Euclidean distance, Pearson's correlation factor, and dynamic time warping methods [28] .
However, hierarchical clustering is heuristic in nature. Another approach is to model the underlying data, rather than defining a distance metric. This has the benefit that new patients can be assigned a probability of belonging to any of the clusters, and the clusters are defined by a generative model. The parameters can therefore be used as identifying descriptions for the given cluster. Particularly within a Bayesian framework, generative mixture models also can very easily handle missing data through marginalisation. The common starting point for such modelling is the Gaussian mixture model (GMM), though depending on one's data types, Bernoulli or categorical mixture models (which follow the same framework) may be appropriate. We will not go into the derivations of mixture modelling here; References 29 and 30 provide excellent introductions to this material. Mixture modelling essentially makes the 
For two data points, x 1 , x 2 , with feature dimension D.
assumption that the underlying data can be separated into discrete latent variables, defined by the number of clusters, K, and a set of parameters to describe the underlying parametric cluster distributions. In a GMM, for instance, these parameters would be the mean μ k and covariance k for every cluster. A challenge, not particular to modelling of chronic disease patients, but certainly encountered in this application, is the high-dimensional nature of the data involved. For instance, suppose we have D = 500 continuous clinical measurements available for a set of patients, and we wish to model these patients with a Gaussian mixture model. This means that 628, 754 parameters would need to be fit in order to model K = 5 clusters with full covariance functions. While feasible with large numbers of patients, access to patients is often challenging in medical applications; the model becomes impossible to fit if less than 500 patients are available (as will be covered shortly, modifications have been developed to handle this situation). This high-dimensional situation is particularly common when incorporating genetic data. For instance, a full microarray will contain > 100, 000 SNPs. If the included SNPs are not filtered prior to modelling their distribution across patients, the use of the basic generative clustering models necessitates impossibly large patient sample sizes.
One approach for managing a large number of variables is to regularise the model, for instance by applying L1 (ridge) or L0 (lasso) penalties. Another approach to dealing with the situation of a large number of variables is to assume that the "true" number of variables is much smaller, and that the dimensionality of the problem can be greatly reduced. This is essentially assuming that there is a continuous latent space upon which the data can be projected (in contrast to the discrete latent space of mixture models). These models, latent factor models, attempt to find a low-dimensional representation, L, of some D-dimensional data, X onto a subspace of dimension M . So L = SX + ε, where S is termed the loading matrix (of size M by N ), and ε is some Gaussian noise; we will say W = S −1 . In other words, it is a matrix factorisation of one matrix (X ) into two low-rank matrices (W and L). Principal component analysis (PCA), independent component analysis (ICA), and canonical correlation analysis are all special cases of latent factor models.
PCA attempts to find an orthogonal projection of some input data that maximises the variance of the projected data. We can derive PCA in a probabilistic way from our framework above (X = WL + ε), if we assume that the latent variables are normally distributed with isotropic covariance: L ∼ N (μ, I), and that the noise is also Gaussian: ε ∼ N (0, σ 2 I). This means that X |L ∼ N (WL, σ 2 I). When maximum likelihood is used to estimate the parameters of this model, this yields the PCA result. The full probabilistic formulation is sometimes termed probabilistic PCA (pPCA). When the model is relaxed and the latent variables are no longer assumed to have a Gaussian distribution, this is equivalent to ICA.
As the above outline derivation suggests, all of these clustering models can be approached from first principles from a Bayesian graphical modelling framework, with priors specifying the required constraints. In linear regression, for example, L1 regularisation is equivalent to placing Gaussian priors over the weight vector. To induce sparsity in the loading matrix S, spike-and-slab and automatic relevance detection (ARD) priors have been proposed. Spike-and-slab priors place large probability mass at zero, with uniform low probability mass elsewhere [31] ; ARD priors consist of hyperparameters governing each weight vector (e.g., a Gaussian prior over each weight vector), such that when the values of the hyperparameters approach infinity, a given weight parameter is dropped from the model. Engelhardt and Stephens explain how mixture models can also be formulated as latent factor models, with modelling choices such as Bayesian priors acting as constraints on the matrix factorisation [32] . Reference 33 explains how various model-based mixture methods build upon each other and are related.
When this perspective is taken, it becomes more apparent how to combine design principles to develop a modelling approach specific to the problem at hand. For instance, models have been developed that combine aspects of both latent continuous and discrete variables. These can be viewed as mixtures of pPCA decompositions, so that within each mixture component, there is a different PCA decomposition.
Modelling choices applicable to chronic disease applications
There are many examples of how models may be developed for a particular question in identifying patient subgroups; we present a few examples here. Schulam et al. use a latent variable approach combined with a generative GP model of time series to capture consistent progression trajectories in patients with scleroderma [13] . Scleroderma is a connective tissue disease in which patients may experience different subsets of symptoms to varying degrees. The authors modelled specialised clinical variables and also employed additional covariates to help explain some of the patient variability.
Ross and Dy developed a non-parametric model for clustering chronic obstructive pulmonary disorder (COPD) patient time-series data [34] . They used a Dirichlet mixture of GPs, performing inference using variational methods. They also allowed for domain knowledge through the inclusion of "must-link" and "cannot-link" constraints. Ross et al. further extended this method to allow for certain features to be important only in certain groups and to allow individuals to belong to multiple groups [35] . They formulated this as a dual beta process over GPs, again performing variational inference to determine the most probable clusters in their application of COPD patient subtypes. They related these subgroups to the presence of several genetic mutations known to be associated with certain forms of COPD.
Kirk et al. used a Dirichlet-multinomial allocation mixture model (a finite approximation to a Dirichlet Process mixture model) to integrate multiple datasets [36] . The underlying idea is that the clustering within one dataset informs the clustering in other datasets, which the authors refer to as "correlated clustering." The study used GP models (for time-series gene expression data) combined with multinomial models (for discrete gene expression data), with comparable performance to other clustering methods, but with the advantage of being able to incorporate more than two distinct data types. Kirk et al. applied this method to identify genes with similar behaviour across yeast datasets, but such a method could also conceivably be used to identify clusters of patients with similar disease trajectories.
Zhao et al. developed a Bayesian group factor analysis model, which is an extension of factor models to the case of multiple observation matrices [37] . Their goal is to capture the covariance structure of a low-rank approximation to their original data X . They therefore place a sparsity-inducing prior on the loading matrix S: the three parameter Beta prior. This model is applicable to the problem of finding gene subsets that are co-regulated.
Clustering extensions
While some data is best formulated as a matrix, sometimes it makes more sense as a tensor. Just as matrices can be decomposed, tensors can also be decomposed in various ways. Kolda and Bader provide a review of the general techniques, the most notable of which include Parafac and Tucker decompositions [38] . Parafac decomposition is a generalisation of singular value decomposition (SVD) to higher dimensions, while Tucker decomposition is essentially a higher-dimensional form of PCA. Parafac can be formulated as a special case of Tucker decomposition. In Parafac, a tensor is decomposed into a sum of first-order tensors that describe each dimension of the tensor; in Tucker, a tensor is decomposed into a core, compressed tensor, which is multipled by additional matrices that describe each tensor mode.
Tensor-based methods are particularly appropriate when examining data collected across repeated experiments or consistent time points, such as often encountered with gene expression experiments. For instance, if 300 patients have the same 100 mRNA levels measured across 10 different experiments where various pathways are stimulated, this data naturally makes sense as a 300 × 100 × 10 tensor. A decomposition may reveal which mRNAs are consistently involved across patients in certain types of experimental scenarios. While gene expression data is currently less commonly available in large biobank repositories, this is likely to change in the future.
Practical considerations in unsupervised clustering
An important aspect of clustering is determining the stability of the identified clusters. For instance, just as evaluation of a supervised machine-learning model's performance will involve cross-validation to estimate the model performance across different subsets of the data, an unsupervised clustering across an entire dataset is vulnerable to the idiosyncrasies of the given dataset. To better assess the generality of the identified clusters, it is recommended that the dataset is resampled multiple times to repeatedly evaluate clustering structure.
Of course, since there is usually no known "true" clustering when attempting to identify patient phenotypes, the identified clusters must be compared in some way across sampling iterations. This is not a trivial task, as the cluster label will change with different iterations of the algorithm, and the composition of assigned patients to each cluster will vary (unless the clusters are extremely well defined). If a non-parametric clustering model is being used, then the number of clusters may also vary across iterations. There are many metrics that can be used to compare the similarity of clusters that are generated from the same underlying dataset, some of which are presented in Table 11 .2. Each cluster in one iteration of a subsampling can be compared with each cluster in another iteration using one of these metrics to "match" clusters across iterations. The overall consistency across subsamplings can then be compared. While some of these indices, such as the Rand index, rely on a "true" label, a single instance I 0 of the subsampling procedure can be identified as the "true" label, and other clusterings can be compared to I 0 to assess consistency.
Some of these metrics have been further developed to account for chance in cluster similarity. It is particularly important to take chance similarities into account when the number of clusters within the dataset is large. The adjusted Rand index is formulated as ARI = where n ij is the number of patients contained in both cluster A i and B j , a i is the total number of patients in cluster A i , and b i is the total number of patients in cluster B i . Figure 11 .6 illustrates a comparison of different clustering outcomes, ranging from random class assignments (panel a) to perfect agreement (panel b). As is evident, some metrics require first the matching up of corresponding groups. For instance, the JI is only able to match groups with the same label, yielding a low score even in the case of perfect agreement. 
Clustering conclusions
The utility of any identified clusters will depend upon the specific question and whether the featured form of the patient data can answer this question. For instance, a clustering of IBD patients based on various clinical variables may reveal consistent subtypes. However, these groups may not correspond with drug response to infliximab (a last line medication) because the question presented was to find the underlying structure of the input dataset. If patient response to infliximab is determined by some factor not present or captured in the input dataset, then the resulting clusters cannot be expected to be useful for understanding infliximab response. However, since they represent the general structure of the data they might point towards specific sub-populations within the spectrum of IBD symptomology. If training for a specific outcome is of interest, and it is believed that there is latent structure in the data, then unsupervised approaches can also be used within two-step algorithms, to generate features as input for secondary supervised analyses. This is particularly appropriate when it is unclear which aspects of the data may be discriminatory (e.g., within a complex physiologic time series), but it is suspected that underlying structure in the data does exist and correlates to the desired outcome predictor variable. This approach is taken, for example, by Reference 39.
Conclusion
Here, we have presented illustrations of how techniques from machine learning can be used specifically for the purposes of modelling chronic disease. EVT provides a method by which to assess patient severity by providing a principled framework for defining how "abnormal" an extreme measurement may be. This is particularly beneficial for chronic disease applications in which fluctuations of measurements within the normal range are not relevant for treatment, but in which deviations outside of this range become important. We have also explained how clustering techniques can be used to probe the underlying structure of large disease phenotypic cohorts to uncover latent sub-phenotypes. Given the growing evidence that many chronic diseases are in fact composed of patient with similar but distinct underlying disease mechanisms, these methods are particularly important in the application area of chronic disease. The high-dimensional nature of genetic data, combined with the variety of data types commonly encountered in patient databases, motivates the use of specialised clustering techniques, as discussed. The growing availability of data and the increasing research focus on novel machine-learning approaches suggests that the modelling of chronic disease will continue to yield beneficial findings for patients and doctors.
